Mumbai, Feb. 14 -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch

of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark's Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan(R)2

Ophthalmic Solution, 0.005% of Upjohn US 2 LLC.

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan(R) Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing...